Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.01 per share
-
Shares outstanding
-
46.2M
-
Number of holders
-
83
-
Total 13F shares, excl. options
-
14.7M
-
Shares change
-
+680K
-
Total reported value, excl. options
-
$382M
-
Value change
-
+$28.3M
-
Put/Call ratio
-
1.68
-
Number of buys
-
51
-
Number of sells
-
-24
-
Price
-
$26.12
Significant Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q2 2020
99 filings reported holding URGN - UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share as of Q2 2020.
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) has 83 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14.7M shares
of 46.2M outstanding shares and own 31.73% of the company stock.
Largest 10 shareholders include MENORA MIVTACHIM HOLDINGS LTD. (2.95M shares), WELLINGTON MANAGEMENT GROUP LLP (2M shares), BlackRock Inc. (1.47M shares), CREDIT SUISSE AG/ (913K shares), Wildcat Capital Management, LLC (900K shares), Phoenix Holdings Ltd. (897K shares), Migdal Insurance & Financial Holdings Ltd. (738K shares), Clal Insurance Enterprises Holdings Ltd (529K shares), STATE STREET CORP (425K shares), and Horton Capital Management, LLC (383K shares).
This table shows the top 83 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.